The company specializes in developing biomarkers and detection methods based on proprietary epigenetic and molecular technologies. Their tests identify methylation markers for various cancers, including colon cancer, to improve patient outcomes. Promis Diagnostics aims to provide affordable and actionable options for cancer screening, using a highly specific custom detection method and strong performance biomarkers. The company's focus is on developing effective non-invasive options for bladder and colorectal cancer screening, with the vision of enabling patients to lead healthier lives.